China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Exami...( HARBIN China May 4 Asia-FirstCall/ --...),Health

HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Research & Development project for the Company's Sudden Cardiac Death (SCD) Early Examination Kit has been appraised by the Heilongjiang Bureau of Science and Technology. The R&D project was undertaken jointly by China Sky One Medical and Harbin Medical University.

The leader of this project is Prof. Baofeng Yang, the Principal of Harbin Medical University, who is also the Chief Scientist of Chinese National 973 Project and Standing Director of the China Pharmaceutical Alliance. Prof. Yang has dedicated a large part of his career to researching SCD and his fundamental research has led to several breakthroughs. In 2008, Prof. Yang and his research team found that the concentration of a substance called "MicroRNA-1" in human blood has positive correlation with the occurrence of SCD. After detailed clinical studies involving many samples, Prof. Yang concluded that the existence of MicroRNA-1 in human blood is a useful predictor of SCD, and higher concentrations of MicroRNA-1 means a higher probability of SCD. The discovery was published in the Journal of Nature-Medicine. In late 2008, Prof. Yang received the national patent for this discovery.

In order to commercialize SCD diagnostic technology, Harbin Medical University transferred the patent exclusively to Harbin First Bio-Engineering Company Limited, the wholly owned subsidiary of China Sky One Medical, in early 2009. The two parties will collaborate in researching a production method for the SCD Early Examination Kit that in
'/>"/>